Clinical Information

This test is appropriate for patients previously diagnosed wth B-ALL and  may be run at any time point in therapy.

This is a COG approved MRD test for patients enrolled on AALL0932 and AALL1131. Day 8 of COG protocol; other timepoints in therapy also accepted.

Minimal residual disease (MRD) is a powerful prognostic factor for predicting outcome in pediatric B cell acute lymphoblastic leukemia (B-ALL).  This flow cytometry assay is an effective method for measuring MRD and is the COG approved MRD test for patients enrolled on AALL0932 and AALL1131 Day 8 of COG protocol; other time points in therapy also accepted.  White blood cells in a peripheral blood sample are stained with a viability dye and monoclonal antibody to CD10, CD19, CD20, CD34, CD45.  This flow cytometric assay has the ability to enumerate and characterize very small populations of abnormal cells, often as low as 1 in 10,000 cells.